Satellos Bioscience Inc. Common Stock (MSLE)

Price$7.83

Favorite Metrics

Price vs S&P 500 (26W)15.32%

Price vs S&P 500 (4W)8.19%

Market Capitalization$248.10M

All Metrics

Book Value / Share (Quarterly)$2.20

P/TBV (Annual)2.12x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-3.14

Price vs S&P 500 (YTD)47.01%

EPS (TTM)$-1.29

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-1.29

EPS (Annual)$-2.16

ROI (Annual)-43.76%

Cash / Share (Quarterly)$2.24

ROA (Last FY)-40.67%

EBITD / Share (TTM)$-0.60

Cash Flow / Share (Annual)$-3.31

P/B Ratio5.33x

P/B Ratio (Quarterly)2.65x

Net Income / Employee (Annual)$-1

ROA (TTM)-50.48%

EPS Incl Extra (Annual)$-2.16

Current Ratio (Annual)14.16x

Quick Ratio (Quarterly)9.94x

3-Month Avg Trading Volume0.03M

52-Week Price Return57.54%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.20

52-Week High$18.98

EPS Excl Extra (Annual)$-2.16

26-Week Price Return24.06%

Quick Ratio (Annual)13.67x

13-Week Price Return12.78%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.70x

Enterprise Value$146.533

Revenue / Employee (Annual)$0

Cash / Share (Annual)$3.51

3-Month Return Std Dev100.50%

Net Income / Employee (TTM)$-2

ROE (Last FY)-43.76%

EPS Basic Excl Extra (Annual)$-2.16

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.29

ROI (TTM)-54.41%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.41

Price vs S&P 500 (52W)22.44%

Year-to-Date Return50.38%

5-Day Price Return18.74%

EPS Normalized (Annual)$-2.16

ROA (5Y Avg)-132.25%

Month-to-Date Return50.00%

EBITD / Share (Annual)$-2.44

LT Debt / Equity (Annual)0.00x

LT Debt / Equity (Quarterly)0.04x

EPS Basic Excl Extra (TTM)$-1.29

P/TBV (Quarterly)2.65x

P/B Ratio (Annual)2.12x

Book Value / Share (Annual)$3.41

Price vs S&P 500 (13W)9.92%

Beta1.56x

Revenue / Share (TTM)$0.00

ROE (TTM)-54.41%

52-Week Low$6.24

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.14

4.13

4.22

About

Satellos Bioscience is a regenerative medicine company developing novel therapeutics to stimulate and restore muscle function in severe neuromuscular disorders. The company's lead program is an oral therapeutic for Duchenne muscular dystrophy that addresses dysregulation identified as a key driver of disease progression. Satellos' approach targets the root cause of muscle degeneration rather than symptomatic relief, positioning the therapy as a potential disease-modifying treatment.